ALNY compared with ARGX: revenue, margins and what each company keeps, and the suppliers and customers both name

ALNYAlnylam Pharmaceuticals, Inc.

Mkt capRevenueRevenue

ARGXArgenx SE

Mkt capRevenueRevenue

Compare

ALNYAlnylam Pharmaceuticals, Inc.

ARGXArgenx SE

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ALNY

1 of 1at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±11.1%▼−25.13%×2.26

Q2 FY26—▼−28.31%—

Q1 FY26—▲+2.76%—

Feb 12 '26—▼−4.28%—

ARGX1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Oct 22 '26±8.8%▼−1.61%×0.18

= impliedALNY realized, solidARGX realized, hatchedOne scale, both sides: full bar = 29%× = |realized| ÷ impliedSource: market data

ALNYAlnylam Pharmaceuticals, Inc.

164.89▼−5.24%· post 165.53

Mkt cap$22.1BRevenue$1.5BQ3 FY26Revenue$3.7BFY25

ARGXArgenx SE

893.85▼−0.45%· post 895.00

ClosedOct 30 '26

Mkt cap$55.3BRevenue—Revenue—

Compare

ClosedOct 30 '26

ALNYAlnylam Pharmaceuticals, Inc.

ARGXArgenx SE

164.89▼−5.24%post 165.53

Price

893.85▼−0.45%post 895.00

$22.1B

Mkt cap

$55.3B

Q3 FY26$1.5B

Revenue

—

FY25$3.7B

Revenue

—

ALNY164.89▼−5.24%vsARGX893.85▼−0.45%ClosedOct 30 '26